Samsung Pharmaceutical Co., Ltd. (001360) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Samsung Pharmaceutical Co., Ltd. (001360:KRX), powered by AI.

Current Price
₩2,090
P/E Ratio
-13.4
Market Cap
196.8B
Sector
Healthcare
What is the Samsung Pharmaceutical Co., Ltd. stock price forecast?

Samsung Pharmaceutical Co., Ltd. is currently trading at ₩2,090. View real-time AI analysis on Alpha Lenz.

What is Samsung Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Samsung Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Samsung Pharmaceutical Co., Ltd.'s P/E ratio?

Samsung Pharmaceutical Co., Ltd.'s P/E ratio is -13.4.

Samsung Pharmaceutical Co., Ltd.

KRX · 001360
₩2,090
Ask about Samsung Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Samsung Pharmaceutical Co., Ltd. trades at a P/E of -13.4 (undervalued) with modest ROE of -15.4%.

Ask for details

Company Overview

Samsung Pharmaceutical Co., Ltd. is a prominent entity in the pharmaceutical industry, primarily engaged in the research, development, and manufacturing of pharmaceutical and healthcare products. This company plays a key role in addressing diverse healthcare needs by producing a variety of drugs and medical solutions, which include over-the-counter medications, prescription drugs, and other specialized therapeutic products. Samsung Pharmaceutical operates at the intersection of science and healthcare, striving to enhance patient outcomes and overall public health. The company is recognized for its commitment to innovation and quality, leveraging advanced technology and rigorous scientific research to develop effective medical treatments. Operating within highly regulated markets, the company ensures compliance with stringent pharmaceutical standards and regulations, thus maintaining credibility and trust among healthcare professionals and consumers alike. As part of its broader impact, Samsung Pharmaceutical contributes to the healthcare sector by addressing unmet medical needs and supporting the advancement of medical science. It is a significant player in the pharmaceutical market, influencing drug pricing, healthcare access, and fostering pharmaceutical advancements across various regions.

CEO정성택 대표이사
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2024

Profile

₩196,798,745,110Market Cap
₩44,294,231,020Revenue
94.16MShares Out
0Employees

Margins

44.64%Gross
-27.13%EBITDA
-33.48%Operating
-31.81%Pre-Tax
-31.81%Net

Valuation

-13.38P/E
1.78P/B
4.26EV/Sales
-15.50EV/EBITDA
-10.67P/FCF

Growth (CAGR)

-6.91%Rev 3Yr
-0.12%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-12.70%ROA
-15.36%ROE
-12.49%ROIC

Financial Health

₩7,386,162,200Cash & Cash Equivalents
₩15,210,452,200Net Debt
21.35%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Samsung Pharmaceutical Co., Ltd. (ticker: 001360) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $196.8B.

The current price is ₩2,090 with a P/E ratio of -13.38x and P/B of 1.78x.

ROE is -15.36% and operating margin is -33.48%. Annual revenue is $44.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Samsung Pharmaceutical Co., Ltd. (Healthcare) Stock Forecast & Analysis ₩2,090 | Alpha Lenz